Esperion Therapeutics (ESPR) Other Gross PP&E Adjustments (2018 - 2025)
Esperion Therapeutics' Other Gross PP&E Adjustments history spans 8 years, with the latest figure at -$27.1 million for Q4 2025.
- For Q4 2025, Other Gross PP&E Adjustments rose 7.38% year-over-year to -$27.1 million; the TTM value through Dec 2025 reached -$27.1 million, up 7.38%, while the annual FY2025 figure was -$27.1 million, 7.38% up from the prior year.
- Other Gross PP&E Adjustments reached -$27.1 million in Q4 2025 per ESPR's latest filing, down from -$3.3 million in the prior quarter.
- In the past five years, Other Gross PP&E Adjustments ranged from a high of -$730000.0 in Q3 2022 to a low of -$29.2 million in Q4 2024.
- Average Other Gross PP&E Adjustments over 5 years is -$9.6 million, with a median of -$4.6 million recorded in 2021.
- Peak YoY movement for Other Gross PP&E Adjustments: surged 84.87% in 2022, then plummeted 563.26% in 2024.
- A 5-year view of Other Gross PP&E Adjustments shows it stood at -$21.9 million in 2021, then fell by 12.07% to -$24.6 million in 2022, then dropped by 14.3% to -$28.1 million in 2023, then dropped by 4.17% to -$29.2 million in 2024, then rose by 7.38% to -$27.1 million in 2025.
- Per Business Quant, the three most recent readings for ESPR's Other Gross PP&E Adjustments are -$27.1 million (Q4 2025), -$3.3 million (Q3 2025), and -$4.2 million (Q2 2025).